|

Metabolically Armed CD19 CAR-T cells Clinical Trials

4 actively recruiting trials

Also known as: Meta10-19

Pipeline

Early 1: 4

Top Sponsors

  • Zhejiang University2
  • The Children's Hospital of Zhejiang University School of Medicine1
  • He Huang1

Indications

  • Cancer3
  • Systemic Lupus Erythematosus1
  • Lupus1
  • Non-hodgkin Lymphoma,B Cell1
  • Non-hodgkin Lymphoma1

Other4 trials

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Early 1
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Early 1
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Early 1
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.